Patricia Jaaks - Concepedia

Author

Patricia Jaaks

Wellcome Sanger Institute ORCID

Also Known As

Jaaks, Patricia, P Jaaks, P. Jaaks, Patricia AIM Jaaks, Patricia Jaaks

147

Publications

1.9K

Citations

H-Index

Concepts

All Affiliations

Wellcome Sanger Institute European Bioinformatics Institute AstraZeneca (United Kingdom)University Children's Hospital Zurich Joint Research Centre

About

Patricia Jaaks is an author at Wellcome Sanger Institute specializing in cancer research, cell biology, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	2	2	98
2	Cell Biology	2	2	98
3	Pathology	1	1	21
4	Cancer Therapeutics	1	1	77
5	Cellular Biochemistry	1	1	21

Patricia Jaaks

Publications

1.8K

Citations

H-Index

Page 1

	Year	Citations
Effective drug combinations in breast, colon and pancreatic cancer cells Patricia Jaaks, Elizabeth A. Coker, Daniël J. Vis, Nature	2022	433
Integrated cross-study datasets of genetic dependencies in cancer Clare Pacini, Joshua M. Dempster, Isabella Boyle, Nature Communications	2021	317
Transcription Factor Activities Enhance Markers of Drug Sensitivity in Cancer Luz García‐Alonso, Francesco Iorio, Angela Matchan, Cancer Research	2017	220
Drug mechanism‐of‐action discovery through the integration of pharmacological and <scp>CRISPR</scp> screens Emanuel Gonçalves, Aldo Segura‐Cabrera, Clare Pacini, Molecular Systems Biology	2020	108
Direct and selective pharmacological disruption of the YAP–TEAD interface by IAG933 inhibits Hippo-dependent and RAS–MAPK-altered cancers Emilie A. Chapeau, Laurent Sansregret, Giorgio Giacomo Galli, Nature Cancer	2024	104
Patient‐specific logic models of signaling pathways from screenings on cancer biopsies to prioritize personalized combination therapies Federica Eduati, Patricia Jaaks, Jessica Wappler, Molecular Systems Biology Systems BiologyCancer BiopsiesMedicinePersonalized Combination TherapiesPatient‐specific Logic Models	2020	77
SLFN11 informs on standard of care and novel treatments in a wide range of cancer models C Winkler, Joshua Armenia, Gemma N. Jones, British Journal of Cancer	2020	68
AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-xL, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia Srividya B. Balachander, Steven W. Criscione, Kate F. Byth, Clinical Cancer Research	2020	64
Stratification and prediction of drug synergy based on target functional similarity Mi Yang, Patricia Jaaks, Jonathan R. Dry, npj Systems Biology and Applications	2020	58
Targeting hedgehog signaling reduces self-renewal in embryonal rhabdomyosarcoma Sampoorna Satheesha, Gabriele Manzella, Amandine Bovay, Oncogene	2015	53

Page 1